Previous 10 | Next 10 |
2024-05-15 12:53:41 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adaptimmune Therapeutics (NASDAQ: ADAP ) just reported results for the first quarter of 2024. Adaptimmune Therapeutics reported earnings per share of -18 cents. This was b...
2024-05-15 10:07:03 ET Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Conference Call May 15, 2024, 08:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Gavin Wood - Chief Financial Officer Dennis ...
2024-05-15 07:45:41 ET More on Adaptimmune Adaptimmune: Huge Opportunity Amid Their Setback With Genentech Adaptimmune Therapeutics gets $125M in financing from Hercules Capital Adaptimmune falls as Roche strategic collaboration ends Seeking Alpha’s Qu...
2024-05-15 07:36:21 ET More on Adaptimmune Adaptimmune: Huge Opportunity Amid Their Setback With Genentech Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune falls as Roche strategic collaboration ends Seeking Alpha’s Quan...
Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE ); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing infrastructure in place to support afami-cel commercial launch upon approval Data from SPEARHE...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
2024-05-14 13:24:59 ET More on Adaptimmune Adaptimmune: Huge Opportunity Amid Their Setback With Genentech Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune falls as Roche strategic collaboration ends Seeking Alpha’s Quan...
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter ended ...
2024-04-26 11:00:11 ET Summary Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma. Adaptimmune Th...
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...